<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5937">
  <stage>Registered</stage>
  <submitdate>31/05/2016</submitdate>
  <approvaldate>31/05/2016</approvaldate>
  <nctid>NCT02812290</nctid>
  <trial_identification>
    <studytitle>Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation, a Multicenter Study</studytitle>
    <scientifictitle>Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies.</scientifictitle>
    <utrn />
    <trialacronym>INTERLUNG</trialacronym>
    <secondaryid>ATAGC 03</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lung Transplant Rejection</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assign molecular scores (probability) of lung transplant disease in a reference set of 300 transbronchial biopsies. - Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</outcome>
      <timepoint>two years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assign molecular scores (probability) of lung transplant disease in a reference set of 50 mucosal endobronchial biopsies. - Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</outcome>
      <timepoint>two years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  All lung transplant recipients undergoing a biopsy as determined by their surgeon or
             physician.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who declined participation or unable to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>350</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Alfred Hospital, Monash University - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Alberta</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Objective: To evaluate the potential impact of molecular phenotyping of transbronchial
      biopsies in lung transplant recipients with allograft dysfunction, and the potential for
      developing a safer endobronchial mucosal biopsy format.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02812290</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philip F Halloran, MD, PhD</name>
      <address>Faculty of Medicine and Dentistry, University of Alberta</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Konrad S Famulski, PhD</name>
      <address />
      <phone>1 780 492 1725</phone>
      <fax />
      <email>konrad@ualberta.ca</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>